Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000908834-25-000187
Filing Date
2025-05-15
Accepted
2025-05-15 09:23:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 43773
  Complete submission text file 0000908834-25-000187.txt   45648
Mailing Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111
Business Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 (415) 421-2132
Farallon Capital Partners, L.P. (Filed by) CIK: 0001175707 (see all company filings)

EIN.: 943106322 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Subject) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91387 | Film No.: 25949249
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)